NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer

NOX-A12 in Second Oncology Indication: Multiple Myeloma

28-Sep-2012 - Germany

NOXXON Pharma announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer® NOX-A12. CXCL12 signaling has been shown to play an important role in the pathophysiology of MM, especially in the interaction of MM cells with the bone marrow microenvironment. By inhibiting this interaction NOX-A12 sensitizes the cancer cells to chemotherapy.

This is the third Phase IIa trial that NOXXON has started this year following the NOX-E36 Phase IIa for the treatment of diabetic nephropathy in June and the NOX-A12 Phase IIa for the treatment of Chronic Lymphocytic Leukemia in July.

MM is a hematologic or blood cancer that develops in the bone marrow in which normal antibody-pro­ducing cells transform into malignant myeloma. The growth of the cancer cells in the bone marrow blocks production of normal blood cells and antibodies, and also causes lesions that weaken the bone. According to the US National Cancer Institute (NCI), MM is the second most common blood cancer in the United States and accounts for approximately one percent of all cancers.

NOXXON's multi-center, open-label, uncontrolled study will be conducted in Europe on 28 relapsed MM patients who were all previously treated for their cancer. The patients will receive NOX-A12 in combination with a background therapy of Velcade®/bortezomib and dexamethasone (VD). Combina­tion treatment with NOX-A12 and VD will occur in 8 cycles of 21 days, with a follow-up period of one year. Each patient will receive up to three different doses of NOX-A12 as part of an individualized dose titration. The primary efficacy endpoint of the study will be the overall response rate, which includes patients with complete and partial responses to therapy. NOXXON expects interim results to be avail­able by the end of 2012.

Other news from the department research and development

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics

Last viewed contents

UCB receives CHMP positive opinion on bringing Neupro back to all patients in Europe - CHMP recommends lifting of treatment restrictions for Neupro in Europe

Paion initiates programme of next generation plasminogen activators

A macromolecular shredder for RNA

A macromolecular shredder for RNA

Study links vitamin D to lung cancer survival - U-M researchers find high levels of enzyme that blocks vitamin D can predict lung cancer survival, U-M study finds

Iowa State researchers looking for catalyst that allows plants to produce hydrocarbons

Affitech Gains Exclusive Worldwide Rights to Develop and Commercialize New Anti-VEGF Antibodies

CRISPR treats genetic disorder in adult mammal

Avastin Approved in Europe for First-line Treatment of Patients With Advanced Lung Cancer - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients

A Potential New Therapeutic Approach for Curing Neurodegenerative Diseases - Reactivating Damaged Motor Neurons Using Magnetic Fields

A Potential New Therapeutic Approach for Curing Neurodegenerative Diseases - Reactivating Damaged Motor Neurons Using Magnetic Fields

PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren

Hummingbird Diagnostics and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

Benefits of combined hormonal contraceptives continue to outweigh risks - Product information to be updated to help women make informed decisions about their choice of contraception